Tian Xinping, Zhao Jiuliang, Song Yijun, Wang Qian, Li Mengtao, Liu Juntao, Zeng Xiaofeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science& Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
Department of Obstetrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Rheumatol Immunol Res. 2023 Sep 27;4(3):115-138. doi: 10.2478/rir-2023-0019. eCollection 2023 Sep.
Systemic lupus erythematosus (SLE), a prevalent autoimmune disease predominantly affecting women of childbearing age, presents ongoing challenges despite notable advances in diagnosis and treatment. Although survival rates for SLE patients have significantly improved, pregnancy continues to pose a considerable obstacle. Addressing this critical need for enhanced reproductive and prenatal care, there is a pressing imperative to establish standardized protocols for peri-gestational monitoring and treatment in SLE patients. This guideline is jointly sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), the Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR), and the Chinese Research Committee of Pregnancy and Reproduction in Autoimmune Rheumatic Diseases (CHOPARD). Thirteen pertinent clinical questions have been generated through several rounds of rigorous clinical and methodological expert discussions and selections for a comprehensive understanding of key aspects in this domain. Guided by thorough examination of research evidence and expert perspectives, the formulated recommendations aim to optimize pregnancy success rates, reduce maternal and infant mortality rates, and ultimately enhance the overall well-being of SLE patients.
系统性红斑狼疮（SLE）是一种常见的自身免疫性疾病，主要影响育龄女性，尽管在诊断和治疗方面取得了显著进展，但仍面临持续挑战。虽然SLE患者的生存率有了显著提高，但妊娠仍然是一个相当大的障碍。为满足对加强生殖和产前护理的这一关键需求，迫切需要为SLE患者制定围孕期监测和治疗的标准化方案。本指南由国家皮肤与免疫疾病临床医学研究中心（NCRC-DID）、中国系统性红斑狼疮治疗与研究组（CSTAR）以及中国自身免疫性风湿疾病妊娠与生殖研究委员会（CHOPARD）联合发起。通过几轮严格的临床和方法学专家讨论及筛选，提出了13个相关临床问题，以全面了解该领域的关键方面。在对研究证据和专家观点进行全面审查的指导下，制定的建议旨在优化妊娠成功率，降低母婴死亡率，并最终提高SLE患者的整体健康水平。
